โณ Fetching live dividend data...
Home โบ Calculator โบ HCM Dividend Calculator 2026
HUTCHMED (China) Limited ยท NASDAQ
Price: $13.80 ยท Annual div: None ยท Frequency: โ ยท Payout ratio: N/A ยท Ex-div: โ
HCM is not a dividend-focused stock
HCM pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
HUTCHMED (China) Limited (HCM) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
No. HUTCHMED (China) Limited (HCM) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. HCM has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data ยท open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. ยท Privacy Policy
Ready to invest? Open HCM position with:
Real after-tax yield depends on where you live and how you hold HCM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| ๐บ๐ธ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| ๐บ๐ธ US Taxable (15%) โ | 15% | 0.00% | -2.80% | $0 / yr |
| ๐บ๐ธ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| ๐ฌ๐ง UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| ๐ฌ๐ง UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| ๐จ๐ฆ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| ๐จ๐ฆ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| ๐ฆ๐บ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| ๐ฆ๐บ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| ๐ฉ๐ช DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| ๐ซ๐ท FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr ยท ๐บ๐ธ US Taxable (15%) ยท static projection (no growth assumed).
HCM pays quarterly โ 4 times per year. Ex-div: โ.
How HCM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024โ2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for HCM sourced from FMP /financial-growth endpoint โ real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2026-05-20 | 30,157 | โ | โ | ||
| J-Other | 2026-05-20 | 26,307 | โ | โ | ||
| J-Other | 2026-05-20 | 7,644 | โ | โ | ||
| J-Other | 2026-05-20 | 7,445 | โ | โ | ||
| J-Other | 2026-05-20 | 132,864 | โ | โ | ||
| J-Other | 2026-05-20 | 75,140 | โ | โ | ||
| J-Other | 2026-05-20 | 8,863 | โ | โ | ||
| J-Other | 2026-05-20 | 5,176 | โ | โ | ||
| Other | 2023-06-05 | 4,520 | $12.51 | $56.5K | ||
| Other | 2019-12-11 | 400,000 | โ | โ |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare HCM with peers: HCM vs AAPG ยท HCM vs ANL ยท HCM vs BNTX
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores โ lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the HCM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer โ
HUTCHMED (China) Limited (HCM) is currently trading at $13.80, 15% below its 52-week high. It does not currently pay a regular dividend.
HUTCHMED (China) Limited (HCM) is a healthcare stock trading at $13.80. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only โ not financial advice.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
โฑ๏ธ Takes 30 seconds ยท No signup ยท Free forever